Table 2.
Tumor treatment, staging and patient outcomes
| Feature | n (valid %) | |||
|---|---|---|---|---|
| Gastrectomy | Subtotal | 141 (69.5%) | ||
| Total | 62 (30.5%) | |||
| Adjuvant therapy | 36 (22%) | |||
| pT | T1 | 10 (5.1%) | ||
| T2 | 41 (20.8%) | |||
| T3 | 122 (61.9%) | |||
| T4 | 24 (12.2%) | |||
| pN | N0 | 59 (31.2%) | ||
| N1 | 37 (19.6%) | |||
| N2 | 50 (26.5%) | |||
| N3 | 43 (22.8%) | |||
| TNM stage | I | 28 (15%) | ||
| II | 69 (36.9%) | |||
| III | 90 (48.1%) | |||
| LNMa [mm, mean (SD)] | 10.5 (7.33) | |||
| LNRb[mean (SD)] | 0.24 (0.28) | |||
| Extracapsular extension | 69 (52.3%) | |||
| Tumor death | 48 (28.6%) | |||
| Recurrence | Total | 87 (43.5%) | ||
| Type | Locorc | 31 (35.2%) | ||
| Distant | 57 (64.8%) | |||
| OSd [months, median (range)] | 29 (0-205) | |||
| DFSe [months, median (range)] | 14.5 (0-186) | |||
aLNM: Lymph node metastases. bLNR: Lymph node ratio. cLocor: Locoregional. dOS: Overall survival. eDFS: Disease-free survival